Drug Profile
Somatropin - Genentech
Alternative Names: Nutrophin; Nutropin; Nutropin Aq; NutropinAq; SMP 140Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech
- Developer Genentech; Ipsen; Roche; Sumitomo Pharma
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Short stature; Somatotropin deficiency; Turner's syndrome
- No development reported Fibromyalgia
Most Recent Events
- 24 Apr 2023 Ipsen plans to discontinue distribution of somatropin in Australia, European Union and the United Kingdom in the 2024
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 08 Jan 2019 Genentech and University of Texas Southwestern Medical Center withdraws a phase II/III trial in HIV infection (In children) in USA prior to enrolment (SC) (NCT00256555)